The skeletal-related events of denosumab versus zoledronic acid in patients with bone metastases: A meta-analysis of randomized controlled trials
Objective: The meta-analysis was used to evaluate the skeletal-related events (SREs) and efficacy of denosumab versus zoledronic acid (ZA) in patients with bone metastases. Methods: The data of this meta-analysis study were searched from PUBMED, EMBASE, Cochrane Library, Web of Science with Conferen...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2017-11-01
|
| Series: | Journal of Bone Oncology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2212137416300859 |
| _version_ | 1818245451816632320 |
|---|---|
| author | Zhicai Zhang Feifei Pu Zengwu Shao |
| author_facet | Zhicai Zhang Feifei Pu Zengwu Shao |
| author_sort | Zhicai Zhang |
| collection | DOAJ |
| description | Objective: The meta-analysis was used to evaluate the skeletal-related events (SREs) and efficacy of denosumab versus zoledronic acid (ZA) in patients with bone metastases. Methods: The data of this meta-analysis study were searched from PUBMED, EMBASE, Cochrane Library, Web of Science with Conference Proceedings, Elsevier and China National Knowledge Infrastructure (CNKI) databases till August 2017. Two independent reviewers reviewed the reference lists of relevant articles. The fixed-effects model and random-effects model were used to summarize relative estimates and 95% confidence intervals (CIs) according to the heterogeneity of the included studies. Results: Three randomized controlled trials (RCTs) including 4050 patients were identified in this meta-analysis study. The pooled analysis showed that denosumab could significantly reduce SREs, series SREs [Odds Ratio (OR) = 0.84; 95% CI, 0.74â0.95, I2 = 0%, P = 0.008] in patients with bone metastases as compared with ZA. Similar results of spinal cord compression SRE and surgery to bone SRE were obtained with (OR = 0.84; 95% CI, 0.70â1.01, I2 = 0%, P = 0.07) and (OR = 0.92; 95% CI, 0.78â1.08, I2 = 0%, P = 0.28) separately, radiation to bone SRE (OR = 0.72; 95% CI, 0.46â1.10, I2 = 11%, P = 0.13) and pathological fracture SRE (OR = 0.78; 95% CI, 0.35â1.73, I2 = 25%, P = 0.54) showed similar results, there were no significant difference between denosumab and ZA in patients with bone metastases. Conclusion: Denosumab was more effective than ZA in reducing the incidence of SRE in patients with bone metastases. Keywords: Skeletal-related event, Denosumab, Zoledronic acid, Bone metastases, Meta- analysis |
| first_indexed | 2024-12-12T14:33:08Z |
| format | Article |
| id | doaj.art-a89a828129854af8bd90548b2aad4796 |
| institution | Directory Open Access Journal |
| issn | 2212-1374 |
| language | English |
| last_indexed | 2024-12-12T14:33:08Z |
| publishDate | 2017-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Bone Oncology |
| spelling | doaj.art-a89a828129854af8bd90548b2aad47962022-12-22T00:21:27ZengElsevierJournal of Bone Oncology2212-13742017-11-0192124The skeletal-related events of denosumab versus zoledronic acid in patients with bone metastases: A meta-analysis of randomized controlled trialsZhicai Zhang0Feifei Pu1Zengwu Shao2Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, ChinaDepartment of Orthopedics, Wuhan No.1 Hospital, Wuhan Integrated TCM & Western Medicine Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, ChinaDepartment of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; Corresponding author.Objective: The meta-analysis was used to evaluate the skeletal-related events (SREs) and efficacy of denosumab versus zoledronic acid (ZA) in patients with bone metastases. Methods: The data of this meta-analysis study were searched from PUBMED, EMBASE, Cochrane Library, Web of Science with Conference Proceedings, Elsevier and China National Knowledge Infrastructure (CNKI) databases till August 2017. Two independent reviewers reviewed the reference lists of relevant articles. The fixed-effects model and random-effects model were used to summarize relative estimates and 95% confidence intervals (CIs) according to the heterogeneity of the included studies. Results: Three randomized controlled trials (RCTs) including 4050 patients were identified in this meta-analysis study. The pooled analysis showed that denosumab could significantly reduce SREs, series SREs [Odds Ratio (OR) = 0.84; 95% CI, 0.74â0.95, I2 = 0%, P = 0.008] in patients with bone metastases as compared with ZA. Similar results of spinal cord compression SRE and surgery to bone SRE were obtained with (OR = 0.84; 95% CI, 0.70â1.01, I2 = 0%, P = 0.07) and (OR = 0.92; 95% CI, 0.78â1.08, I2 = 0%, P = 0.28) separately, radiation to bone SRE (OR = 0.72; 95% CI, 0.46â1.10, I2 = 11%, P = 0.13) and pathological fracture SRE (OR = 0.78; 95% CI, 0.35â1.73, I2 = 25%, P = 0.54) showed similar results, there were no significant difference between denosumab and ZA in patients with bone metastases. Conclusion: Denosumab was more effective than ZA in reducing the incidence of SRE in patients with bone metastases. Keywords: Skeletal-related event, Denosumab, Zoledronic acid, Bone metastases, Meta- analysishttp://www.sciencedirect.com/science/article/pii/S2212137416300859 |
| spellingShingle | Zhicai Zhang Feifei Pu Zengwu Shao The skeletal-related events of denosumab versus zoledronic acid in patients with bone metastases: A meta-analysis of randomized controlled trials Journal of Bone Oncology |
| title | The skeletal-related events of denosumab versus zoledronic acid in patients with bone metastases: A meta-analysis of randomized controlled trials |
| title_full | The skeletal-related events of denosumab versus zoledronic acid in patients with bone metastases: A meta-analysis of randomized controlled trials |
| title_fullStr | The skeletal-related events of denosumab versus zoledronic acid in patients with bone metastases: A meta-analysis of randomized controlled trials |
| title_full_unstemmed | The skeletal-related events of denosumab versus zoledronic acid in patients with bone metastases: A meta-analysis of randomized controlled trials |
| title_short | The skeletal-related events of denosumab versus zoledronic acid in patients with bone metastases: A meta-analysis of randomized controlled trials |
| title_sort | skeletal related events of denosumab versus zoledronic acid in patients with bone metastases a meta analysis of randomized controlled trials |
| url | http://www.sciencedirect.com/science/article/pii/S2212137416300859 |
| work_keys_str_mv | AT zhicaizhang theskeletalrelatedeventsofdenosumabversuszoledronicacidinpatientswithbonemetastasesametaanalysisofrandomizedcontrolledtrials AT feifeipu theskeletalrelatedeventsofdenosumabversuszoledronicacidinpatientswithbonemetastasesametaanalysisofrandomizedcontrolledtrials AT zengwushao theskeletalrelatedeventsofdenosumabversuszoledronicacidinpatientswithbonemetastasesametaanalysisofrandomizedcontrolledtrials AT zhicaizhang skeletalrelatedeventsofdenosumabversuszoledronicacidinpatientswithbonemetastasesametaanalysisofrandomizedcontrolledtrials AT feifeipu skeletalrelatedeventsofdenosumabversuszoledronicacidinpatientswithbonemetastasesametaanalysisofrandomizedcontrolledtrials AT zengwushao skeletalrelatedeventsofdenosumabversuszoledronicacidinpatientswithbonemetastasesametaanalysisofrandomizedcontrolledtrials |